Table VI.
Adverse events in patients who received metronomic regimens and in those who did not receive this type of regimen.
| Adverse events | Patients receiving MET (n=52) | Patients not receiving MET (n=26) | P-value |
|---|---|---|---|
| Any grade, n (%) | 19 (36.5) | 16 (61.5) | 0.0376 |
| Grade 3/4, n (%) | 10 (19.2) | 11 (42.4) | 0.0314 |
| Leukopenia | 7 | 5 | |
| Cystitis | 1a | – | |
| Febrile neutropenia | 1 | – | |
| Thrombocytopenia | 1a | – | |
| Hand-foot syndrome | – | 1 | |
| Heart failure | – | 1a | |
| Neuropathy | – | 1a | |
| Pneumonia | – | 1a | |
| Proteinuria | – | 1 | |
| Anorexia | – | 1a |
a
Leading to treatment discontinuation. Bold print indicates statistical significance. MET, metronomic chemotherapy.